Amylgen is a CRO proposing validated in vivo models of neurodegenerative diseases. Ours models and technique allow fast-scale screening and pre-clinical validation for the pharmaceutical development of new drug candidates :
We propose a panel of in vivo rodent models for a variety of CNS disorders like depression, schizophrenia, anxiety and more particulary neurodegenerative diseases like Alzheimer and Parkinson.
We propose on each model, a comprehensive panel of morphological, biochemical analyses and behavioral responses. Experimental protocols vary from basic screening on selected molecular, histological or behavioral outcomes to more comprehensive large scale studies, according to the client’s requests. Control treatments and reference molecules are included.
Ours services have been proven to facilitate decision-making process at critical phases of drug development. Amylgen’s contracting service ans obligations, icluding quality standards and time sensitive deadlines, are fully provided and satisfaction guaranteed.
Location: France, Occitania, Montferrier-sur-Lez
Member count: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Crealia | crealia.or... |